Nanotechnology and COVID-19: quo vadis?

被引:7
|
作者
Tavares, Joao Lima [1 ,2 ]
Cavalcanti, Iago Dillion Lima [1 ,2 ]
Santos Magalhaes, Nereide Stela [1 ]
Lira Nogueira, Mariane Cajuba de Britto [1 ,2 ]
机构
[1] Univ Fed Pernambuco UFPE, Lab Imunopatol Keizo Asami LIKA, Av Prof Moraes Rego,Cidade Univ, BR-12355067 Recife, PE, Brazil
[2] Univ Fed Pernambuco CAV UFPE, Ctr Acad Vitoria, Lab Nanotecnol Biotecnol & Cultura Celulas, Recife, PE, Brazil
关键词
COVID-19; Nanomedicine; Nanocarriers; Liposomes; Nanoparticles; DRUG-DELIVERY; VACCINE; CHALLENGES;
D O I
10.1007/s11051-022-05452-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The pandemic COVID-19 has worried everyone due to the high mortality rate and the high number of people hospitalized with severe acute respiratory syndrome caused by SARS-CoV-2. Given the seriousness of this disease, several companies and research institutions have sought alternative treatment and/or prevention methods for COVID-19. Due to its versatility, nanotechnology has allowed the development of protective equipment and vaccines to prevent the disease and reduce the number of severe COVID-19 cases. Thus, this article combined the main works and products developed in a nanotechnological field for COVID-19. We performed a literature search using the keywords "COVID-19," "SARS-CoV-2," "nanoparticles," "nanotechnology," and "liposomes" in the SciELO, Scifinder, PubMed, Sciencedirect, ClinicalTrials, and Nanotechnology Products databases Database. The data survey indicated 48 articles, 62 products, and 32 patents. The use of nanotechnology against COVID-19 has brought benefits in several parameters of this disease, helping develop rapid diagnostic tests that release the result in 10 min, as well as developing vaccines containing genetic material from SARS-CoV-2 (DNA, mRNA, and protein subunits). Nanotechnology is an exceptional ally against COVID-19, contributing to the most diverse areas, helping both prevent, diagnose, and treat COVID-19.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Quo vadis public debt? [Staatsverschuldung quo vadis?]
    Neumann M.
    List Forum für Wirtschafts- und Finanzpolitik, 2006, 32 (2) : 137 - 155
  • [42] COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
    Chung, Young Hun
    Beiss, Veronique
    Fiering, Steven N.
    Steinmetz, Nicole F.
    ACS NANO, 2020, 14 (10) : 12522 - 12537
  • [43] The role of nanotechnology in current COVID-19 outbreak
    Tavakol, Shima
    Zahmatkeshan, Masoumeh
    Mohammadinejad, Reza
    Mehrzadi, Saeed
    Joghataei, Mohammad T.
    Alavijeh, Mo S.
    Seifalian, Alexander
    HELIYON, 2021, 7 (04)
  • [44] QUO VADIS
    Hagie, C. E.
    SCHOOL AND SOCIETY, 1935, 41 (1051): : 227 - 229
  • [45] Quo vadis?
    Muhl, ZF
    Carlson, M
    AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 1999, 115 (04) : 25A - 26A
  • [46] Quo vadis?
    Mitchinson, MJ
    LANCET, 1996, 348 (9043): : 1738 - 1738
  • [47] QUO VADIS
    HENDERSON, SE
    PHYLON, 1967, 28 (02) : 214 - 216
  • [48] Quo vadis?
    Smith, FJ
    BRITISH MEDICAL JOURNAL, 1917, 1917 : 856 - 856
  • [49] Quo vadis ... ?
    Evans, Owen
    Harper, Graeme
    STUDIES IN EUROPEAN CINEMA, 2016, 13 (03) : 183 - 184
  • [50] QUO VADIS
    FIELD, J
    VETERINARY RECORD, 1972, 90 (26) : 740 - &